AOTMiT: Transparency Council on diabetes treatment, among other things

Agenda:

1. Preparation of a position paper on the evaluation of the drug Keytruda (pembrolizumabum) in combination with axitinib within the framework of the drug program B.10. "Treatment of patients with renal cell carcinoma" (ICD-10: C64).
2. Preparation of a position paper on the evaluation of the drug Keytruda (pembrolizumab)
   under drug program B.58. "Treatment of patients with cancer of the esophagus, gastroesophageal junction and stomach" (ICD-10: C15-C16, HER2-).
3. Prepare a position paper on the evaluation of the drug Diaflix (dapagliflozinum) for the indications:
   
   1. In adult patients and children aged 10 years and older for the treatment of inadequately controlled type 2 diabetes, as adjunctive treatment to diet and physical activity:
      - in monotherapy, when the use of metformin is inappropriate due to intolerance,
      - in combination with other medicinal products for the treatment of type 2 diabetes;
   2. Treatment of chronic kidney disease in adults;
   3. Treatment of symptomatic chronic heart failure in adults.
4. Preparation of an opinion on the draft health policy program of the local government unit
   "Program for prevention of depressive disorders in the youth population in the Municipality of Grębocice for 2026-2030".
5. Preparation of an opinion on the draft health policy program of the local government unit
   "Health policy program for medical rehabilitation of residents of the Municipality of Grębocice for 2026-2030".

Source: AOTMiT